{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T10:49:22Z","timestamp":1791715762400,"version":"4.3.4"},"reference-count":73,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Guiding scientific Research Project of Shiyan Science and Technology Bureau","award":["25Y158"],"award-info":[{"award-number":["25Y158"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Cholangiocarcinoma (CCA) is an aggressive malignancy characterized by a poor prognosis, where timely diagnosis and accurate staging are critical yet challenging. Conventional imaging techniques often fail to effectively differentiate primary lesions from micrometastases or to distinguish benign from malignant findings. Fibroblast activation protein (FAP), highly expressed in cancer-associated fibroblasts, presents a promising molecular target for improving diagnostic precision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      This review synthesizes current clinical evidence regarding the application of technetium-99m-labeled FAP inhibitors (\n                      <jats:sup>99m<\/jats:sup>\n                      Tc-FAPI) in single-photon emission computed tomography\/computed tomography (SPECT\/CT) for the detection of primary and metastatic cholangiocarcinoma. The analysis focuses on the diagnostic performance, sensitivity, and clinical utility of\n                      <jats:sup>99m<\/jats:sup>\n                      Tc-FAPI SPECT\/CT compared to standard imaging modalities such as contrast-enhanced CT and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Literature indicates that FAP is expressed in over 93% of cholangiocarcinoma stroma, providing a strong rationale for FAPI imaging. Clinical studies demonstrate that\n                      <jats:sup>99m<\/jats:sup>\n                      Tc-FAPI SPECT\/CT effectively detects primary lesions with performance comparable to\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT. Notably, it exhibits superior sensitivity for identifying lymph node and peritoneal metastases compared to contrast-enhanced CT, detecting a higher number of lesions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>99m<\/jats:sup>\n                      Tc-FAPI SPECT\/CT holds significant potential as a valuable tool for the diagnosis and staging of cholangiocarcinoma, serving as an effective complement to existing imaging methods. Despite challenges such as lower spatial resolution and the need for standardized protocols, the modality offers economic and logistical advantages. Further well-designed, large-scale studies are required to validate these findings and support broader clinical adoption.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10849785261431301","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T10:41:53Z","timestamp":1774694513000},"page":"759-772","source":"Crossref","is-referenced-by-count":0,"title":["Analysis and Outlook on the Use of\n                    <sup>99m<\/sup>\n                    Tc-FAPI SPECT\/CT in the Diagnosis of Primary and Metastatic Lesions of Cholangiocarcinoma"],"prefix":"10.1177","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4980-4812","authenticated-orcid":false,"given":"Xue","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfan","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Renmin Hospital, Hubei University of Medicine, Shiyan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14101"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1709910"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-20-396"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-003-0011-z"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.14.12830"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000453009"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01710.x"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/13651820801992617"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005348"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16593-y"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003489"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05706-y"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.854658"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph18040522"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-024-00264-0"},{"issue":"5","key":"e_1_3_2_17_1","first-page":"373","article-title":"[Current developments in SPECT\/CT systems using 99mTc-radiopharmaceuticals]","volume":"59","author":"Ferro-Flores G","year":"2007","unstructured":"16.Ferro-Flores G, , de Murphy CA. [Current developments in SPECT\/CT systems using 99mTc-radiopharmaceuticals]. Rev Invest CLIN 2007;59(5):373\u2013381.","journal-title":"Rev Invest CLIN"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00203371"},{"issue":"09","key":"e_1_3_2_19_1","first-page":"36","article-title":"Diagnostic effectiveness of ultrasound and combined ultrasound with CT, ERCP, and MRI in hepatobiliary duct stones complicated by hepatobiliary duct cancer","volume":"6","author":"Li J","year":"2014","unstructured":"18.Li J, , Hu JW. Diagnostic effectiveness of ultrasound and combined ultrasound with CT, ERCP, and MRI in hepatobiliary duct stones complicated by hepatobiliary duct cancer. Chin Med Front 2014;6(09):36\u201338.","journal-title":"Chin Med Front"},{"issue":"03","key":"e_1_3_2_20_1","first-page":"111","article-title":"Comparative diagnostic value of ultrasound, CT, ERCP, and MRCP for choledochal carcinoma complicating hepatobiliary duct stones","volume":"23","author":"Wu CJ","year":"2014","unstructured":"19.Wu CJ. Comparative diagnostic value of ultrasound, CT, ERCP, and MRCP for choledochal carcinoma complicating hepatobiliary duct stones. Henan Med Res 2014;23(03):111\u2013112.","journal-title":"Henan Med Res"},{"issue":"10","key":"e_1_3_2_21_1","first-page":"1693","article-title":"Diagnostic value of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in cholangiocarcinoma","volume":"21","author":"Su DW","year":"2017","unstructured":"20.Su DW, , Fu XD, , Yu JN, et al. Diagnostic value of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in cholangiocarcinoma. Chin J Lab Diagn 2017;21(10):1693\u20131695.","journal-title":"Chin J Lab Diagn"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-11606-0"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.4103\/2384-5147.136823"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142301"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1067\/mge.2002.125105"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S243417"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.sabcs11-p1-03-09"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnume.2024.1480471"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.62347\/JXZI9315"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1967\/s002449912724"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2025.01.008"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/RCT.0000000000001638"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/go.2023.9.supplement_1.60"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15060729"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-025-01691-6"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14151"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102531"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4354235"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1708449"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2973"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2019.10.005"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01342-6"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2017-2951"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217475"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2024.04.026"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16015"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07093-6"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2023.2296668"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03436-1"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.239731"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c02062"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00031"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c01094"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001224"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00712"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27010264"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2025.06.011"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.23736\/S1824-4785.24.03603-3"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058347"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.150565"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005877"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c00783"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005112"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265215"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8969714"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06068-1"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1462870"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1258\/002221505774783430"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2023.0411"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003056"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13183012"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.4_suppl.407"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1891\/2380-9418.10.2.135"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264205"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10849785261431301","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10849785261431301","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10849785261431301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T10:19:53Z","timestamp":1791713993000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10849785261431301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":73,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11,1]]}},"alternative-id":["10.1177\/10849785261431301"],"URL":"https:\/\/doi.org\/10.1177\/10849785261431301","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]}}}